ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.

Leadership Team

Jaume Pons, PhD

President and Chief Executive Officer

Chris Byrd, JD, PhD

General Counsel

Peter García

Chief Financial Officer

Jeanne Jew

Chief Business Officer

Shelly Pinto

Vice President, Finance and Chief Accounting Officer

Sophia Randolph, MD, PhD

Chief Medical Officer

Management Team

Yeong-Liang Lin, MD, MS

Senior Vice President, Drug Safety and Pharmacovigilance

Athanasios Tsiatis, MD

Senior Vice President, Clinical Development

Michael Chang, PhD

Vice President, Operations

Hadi Falahatpisheh, DVM, PhD, DABT

Vice President, Preclinical Development

Sue Naim

Vice President, Clinical Operations

Hank Stern

Vice President, Chemistry, Manufacturing and Controls

Susan Vermeir

Vice President, Regulatory Affairs

Marija Vrljic, PhD

Vice President, Antibody Technologies